CZ181094A3 - Pharmaceutical compositions exhibiting excellent solubility - Google Patents

Pharmaceutical compositions exhibiting excellent solubility Download PDF

Info

Publication number
CZ181094A3
CZ181094A3 CZ941810A CZ181094A CZ181094A3 CZ 181094 A3 CZ181094 A3 CZ 181094A3 CZ 941810 A CZ941810 A CZ 941810A CZ 181094 A CZ181094 A CZ 181094A CZ 181094 A3 CZ181094 A3 CZ 181094A3
Authority
CZ
Czechia
Prior art keywords
weight
salt
sodium
pharmaceutical composition
ifetroban
Prior art date
Application number
CZ941810A
Other languages
Czech (cs)
English (en)
Inventor
Faranak Nifkar
Abu T M Serajuddin
Robert L Jerzewski
Nemichand B Jain
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CZ181094A3 publication Critical patent/CZ181094A3/cs

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CZ941810A 1993-08-02 1994-07-28 Pharmaceutical compositions exhibiting excellent solubility CZ181094A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10080293A 1993-08-02 1993-08-02

Publications (1)

Publication Number Publication Date
CZ181094A3 true CZ181094A3 (en) 1995-02-15

Family

ID=22281616

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ941810A CZ181094A3 (en) 1993-08-02 1994-07-28 Pharmaceutical compositions exhibiting excellent solubility

Country Status (15)

Country Link
EP (1) EP0638310A1 (enExample)
JP (1) JPH07145052A (enExample)
KR (1) KR950005309A (enExample)
CN (1) CN1118254A (enExample)
AU (1) AU6878294A (enExample)
CA (1) CA2129099A1 (enExample)
CZ (1) CZ181094A3 (enExample)
FI (1) FI943569A7 (enExample)
HU (1) HUT70951A (enExample)
IL (1) IL110376A (enExample)
NO (1) NO942854L (enExample)
NZ (1) NZ264129A (enExample)
PL (1) PL304508A1 (enExample)
RU (1) RU94028273A (enExample)
ZA (1) ZA945672B (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0839526A3 (en) * 1996-10-31 1999-01-07 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation with fast buccal disintegration or dissolution
CN1195500C (zh) 1998-05-18 2005-04-06 武田药品工业株式会社 可口腔崩解的片剂
CA2581111A1 (en) 1998-07-28 2000-02-10 Takeda Pharmaceutical Company Limited Rapidly disintegrable solid preparation
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
JP4698000B2 (ja) * 2000-06-27 2011-06-08 旭化成ケミカルズ株式会社 水易溶性薬物含有錠剤
WO2002072069A1 (en) * 2001-03-12 2002-09-19 Novo Nordisk A/S Novel tablets and capsules and a process for its preparation
US20030070584A1 (en) * 2001-05-15 2003-04-17 Cynthia Gulian Dip coating compositions containing cellulose ethers
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
DE10341414A1 (de) * 2003-09-05 2005-03-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Oral zu applizierende Darreichungsform für schwerlösliche saure und amphotere Wirkstoffe
CN100438914C (zh) * 2003-10-15 2008-12-03 富士化学工业株式会社 用于口腔内快速崩解的片剂的组合物
JP3841804B2 (ja) 2003-10-15 2006-11-08 富士化学工業株式会社 口腔内速崩壊性錠剤用の組成物
US8349361B2 (en) 2003-10-15 2013-01-08 Fuji Chemical Industry Co., Ltd. Composition for rapid disintegrating tablet in oral cavity
EA015304B1 (ru) 2006-08-03 2011-06-30 Нитек Фарма Аг Лечение ревматоидного заболевания глюкокортикоидами с отсроченным высвобождением
MY149356A (en) 2007-03-29 2013-08-30 Daiichi Sankyo Co Ltd Pharmaceutical composition
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
EP3804717A1 (en) 2014-05-16 2021-04-14 Cumberland Pharmaceuticals, Inc. Compositions and methods of treating systemic sclerosis or pulmonary arterial hypertension
US12161632B2 (en) 2014-05-16 2024-12-10 Cumberland Pharmaceuticals Inc. Compositions and methods of treating cardiac fibrosis with ifetroban
MX2017017155A (es) 2015-06-30 2018-08-09 Cumberland Pharmaceuticals Inc Antagonistas del receptor de tromboxano en erea/asma.
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
CN109310646A (zh) 2016-05-05 2019-02-05 阿奎斯蒂弗医疗股份有限公司 增强递送的肾上腺素组合物
EP3454850B1 (en) 2016-05-11 2023-06-21 Cumberland Pharmaceuticals Inc. Compositions and methods of treating muscular dystrophy with thromboxane-a2 receptor antagonists
US12465564B2 (en) 2021-10-25 2025-11-11 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5100889A (en) * 1989-04-03 1992-03-31 E. R. Squibb & Sons, Inc. 7-oxabicycloheptyl substituted heterocyclic amide or ester prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease
DD299186A5 (de) * 1990-10-01 1992-04-02 E.R. Squibb U. Sons,Inc.,Us Phenylen-7-oxabicycloheptyl-substituierte heterocycloamid-prostaglandinanaloga

Also Published As

Publication number Publication date
CN1118254A (zh) 1996-03-13
EP0638310A1 (en) 1995-02-15
AU6878294A (en) 1995-02-09
CA2129099A1 (en) 1995-02-03
NO942854L (no) 1995-02-03
RU94028273A (ru) 1996-11-10
FI943569L (fi) 1995-02-03
IL110376A0 (en) 1994-10-21
FI943569A7 (fi) 1995-02-03
FI943569A0 (fi) 1994-07-29
KR950005309A (ko) 1995-03-20
HU9402254D0 (en) 1994-09-28
IL110376A (en) 1998-08-16
NO942854D0 (enExample) 1994-08-01
NZ264129A (en) 1996-05-28
PL304508A1 (en) 1995-02-06
JPH07145052A (ja) 1995-06-06
ZA945672B (en) 1995-03-06
HUT70951A (en) 1995-11-28

Similar Documents

Publication Publication Date Title
CZ181094A3 (en) Pharmaceutical compositions exhibiting excellent solubility
JP2568230B2 (ja) スフエロイド
CN104136004B (zh) 多西拉敏和吡哆醇和/或其代谢物或盐的制剂
CN113423390B (zh) 阿法比星制剂及其制备方法
WO2018153925A1 (en) Stable pharmaceutical compositions comprising macitentan
PT2468361E (pt) Formulações de vildagliptina
AU2006213439A1 (en) Pharmaceutical composition of acid labile substances
EP2412370A1 (en) Matrix-type sustained release preparation containing basic additive
US20120201886A1 (en) Coated Extended Release Pharmaceutical Compositions Containing Paliperidone
EP3185856B1 (en) Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof
EP1965773B1 (en) Oral formulation of anhydrous olanzapine form i
TWI595874B (zh) 多西拉敏及吡哆醇及／或其代謝產物或鹽之多模式釋放調配物
WO2020003196A1 (en) Pharmaceutical composition of axitinib
US10471156B2 (en) Pharmaceutical composition comprising amorphous lenalidomide
JPH11335302A (ja) 安定な医薬組成物
HUT70759A (en) Stabile pharmaceutical compositions containing ipsapiron having retard effect
US20190070167A1 (en) Pitavastatin containing preparation and method for producing same
KR0184350B1 (ko) 오메프라졸 구강점막 부착 정제 조성물
JP6673798B2 (ja) カペシタビンを有効成分とするフィルムコート医薬製剤
WO2024115680A1 (en) Ribociclib salts and formulations thereof
WO2024225996A1 (en) A new pharmaceutical tablet composition comprising eltrombopag olamine
ES2533613T3 (es) Método de producción de comprimidos farmacéuticos
JP2022113343A (ja) アキシチニブを有効成分とする医薬錠剤
KR20080000121A (ko) 산불안정성 라베프라졸나트륨의 안정화 방법
BR112017004190B1 (pt) Formulação de liberação plurimodal de doxilamina e piridoxina e/ou metabolitos ou sais da mesma